Distinguished in Undifferentiated Pleomorphic Sarcoma

Dr. Katherine Thornton

Oncology
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Undifferentiated Pleomorphic Sarcoma
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katherine Thornton is an Oncologist in Boston, Massachusetts. Dr. Thornton is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Angiosarcoma, Synovial Sarcoma, and Bone Tumor.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Thornton has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Enrollment Status: Recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drugs: INBRX-109 Tetravalent DR5 Agonist Antibody, Carboplatin, Cisplatin, Pemetrexed, 5-Fluorouracil, Irinotecan
Study Phase: Phase 1
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Drug
Study Drug: Rogaratinib
Study Phase: Phase 2
A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drug: Eribulin
Study Phase: Phase 2
An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate
An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Adult Patients With Osteosarcoma Receiving High-Dose Methotrexate
Enrollment Status: Active_not_recruiting
Publish Date: July 15, 2025
Intervention Type: Other, Drug
Study Drug: Glucarpidase
Study Phase: Early Phase 1
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Genetic
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
View 5 Less Clinical Trials

37 Total Publications

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.
Journal: JCO oncology advances
Published: November 06, 2024
Similar Doctors
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Michael J. Nathenson
Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Michael J. Nathenson
Oncology
450 Brookline Ave, Dana-farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-582-9396
Languages Spoken:
English

Michael Nathenson is an Oncologist in Boston, Massachusetts. Dr. Nathenson is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Salpingo-Oophorectomy.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Suzanne George
Oncology | Hematology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Suzanne George
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzanne George is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. George is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. Her top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, and Mesenchymoma. Dr. George is currently accepting new patients.

Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Jeffrey Morgan
Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Jeffrey Morgan
Oncology
44 Binney St, Sw530, 
Boston, MA 
 (0.1 miles away)
617-632-5204
Languages Spoken:
English
See accepted insurances

Jeffrey Morgan is an Oncologist in Boston, Massachusetts. Dr. Morgan is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, Gastrointestinal Stromal Tumor, and Bone Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Thornton's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 8 Advanced Conditions
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile